Break it Down: Dimerix inks major Japanese partnership
Stockhead TV
share
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
In this episode, Fraser Palamara tells all on Dimerix’s (ASX:DXB) new partner in Japan’s FUSO Pharmaceutical Industries to develop a drug candidate in fighting kidney disease.
FUSO will be funding clinical trials in Japan and Dimerix will receive more than equivalent of A$170 million as upfront payment and in sales milestones.
Tune in to get the latest.
While Dimerix is a Stockhead advertiser, it did not sponsor this content.
